Caveolin-1 (CAV-1) up regulation in metabolic syndrome: all roads leading to the same end
- PDF / 671,314 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 105 Downloads / 225 Views
SHORT COMMUNICATION
Caveolin‑1 (CAV‑1) up regulation in metabolic syndrome: all roads leading to the same end Gabriela Montenegro de Souza1 · Maria Eduarda de Albuquerque Borborema1,2 · Thays Maria Costa de Lucena1,2 · Ariane Fernandes da Silva Santos1,2 · Brenda Regina de Lima1,2 · Dinaldo Cavalcanti de Oliveira3 · Jaqueline de Azevêdo Silva1,2 Received: 20 July 2020 / Accepted: 22 October 2020 © Springer Nature B.V. 2020
Abstract Metabolic syndrome (MS) is a set of clinical conditions such as insulin resistance, hyperglycemia, systemic arterial hypertension (SAH), dyslipidemia, obesity and high abdominal circumference. Some of these clinical characteristics have been associated with caveolin-1, a caveolae structural protein, responsible for insulin activation, storage and degradation of cholesterol, and so on. Herein we assessed CAV-1 mRNA levels in MS patients comparing to healthy controls (HC) and according patients’ clinical features. We included 87 patients in the study, 25 patients with MS, 30 patients with at least one clinical condition (diabetes, SAH, dyslipidemia, obesity and high abdominal circumference), 13 with two clinical conditions and 19 HC. CAV-1 mRNA levels from peripheral blood samples were assessed by Real Time qPCR using specific Taqman probe. The analysis was performed using ∆Cq method and the statistical tests Shapiro–Wilk, One-Way ANOVA and Mann– Whitney. We found CAV-1 increased mRNA levels in patients with MS (1.645 FC, p = 9.794 × 10−20) and even higher in patients with only one or two clinical conditions (2.215 FC, p = 1.215 × 10−32 and 1.716 FC, p = 4.197 × 10−05, respectively). When individual clinical conditions were observed, individuals with high abdominal circumference and obesity present a significantly up regulation when compared to HC (2.956 FC, p = 0.0004 and 3.643 FC, p = 0.002, respectively). This work indicates that CAV-1 gene expression from whole blood samples is associated to MS clinical conditions and may become a potential target for MS treatment and prevention. Keywords Caveolin-1 · Type 2 diabetes mellitus · Hypertension · Hyperglycemia · Insulin resistance · Dyslipidemia
Introduction
Gabriela Montenegro de Souza and Maria Eduarda de Albuquerque Borborema equally contributed to this work. * Jaqueline de Azevêdo Silva [email protected] 1
Laboratório de Genética e Biologia Molecular Humana, Departamento de Genética, Universidade Federal de Pernambuco, Av. Prof. Moraes Rego, 1235, Recife, Pernambuco CEP 50760‑901, Brazil
2
Laboratório de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
3
Divisão de Cardiologia, Departamento de Medicina Clínica, Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil
Metabolic syndrome (MS) is characterized as a group of clinical conditions, including systemic arterial hypertension (SAH), insulin resistance, hyperglycemia, dyslipidemia, obesity and high abdominal circumference and lead to health risks as cardiovascular disease (CVD) [1]. MS is diagnosed
Data Loading...
